AI model helps atopic dermatitis patients diagnose complications and malignant diseases

The AI model is detailed in a paper published in the Journal of Dermatological Science on January 11, 2023.

AD is a chronic disease that affects around 12 percent of people and often begins in childhood. Patients with AD typically have a suppressed skin immune barrier, which reduces their protection against microbial pathogens, leading to complications of the eczema from bacterial or viral infections. This may include herpes simplex, impetigo, and Kaposi varicelliform eruption (eczema herpeticum).

Recognizing whether AD has led to any of these complications can be challenging for patients as the symptoms’ appearance on the skin is very similar to AD itself. Moreover, mycosis fungoides, a type of blood cancer that causes skin lesions, can also exhibit similar symptoms to AD and may co-exist with AD. Some medications for AD can even worsen infections or mycosis fungoides.

Proper and early diagnosis of complications and malignant diseases is critical for appropriate treatment and better outcomes. However, patients cannot always recognize any abnormal symptoms and visit a doctor as soon as possible due to the similarity of symptoms.

To address this issue, the team trained their convolutional neural network (CNN) model on non-standard images of AD, impetigo, mycosis fungoides, herpes simplex, and Kaposi varicelliform eruption. They then compared the AI’s diagnosis accuracy to a set of non-standard images manually cropped and diagnostically annotated by dermatologists. They found that their system achieved a diagnostic accuracy almost equal to the manually assessed image set.

The team is currently developing an AI-powered smartphone app to translate their system, enabling patients to manage their skin diseases remotely with just their phone’s camera. They are also experimenting with AD patients to improve the app’s usability.

Yuta Yanagisawa, a researcher with the Tohoku University School of Medicine and co-author of the paper, said, “A dermatologist would of course be able to spot the difference, but it is incredibly impractical for an AD patient to visit a dermatologist every day. If only there were some handy, low-cost mechanism that replicated that dermatologist’s knowledge and could be used during a patient’s daily regimen of checking their skin.”

The team believes that this technology will help patients with skin diseases to manage their conditions effectively and efficiently, resulting in better health outcomes.